Matthew Hawryluk - 31 Jan 2022 Form 4 Insider Report for Gritstone bio, Inc.

Role
Executive Vice President and Chief Business Officer
Signature
/s/ Rahsaan Thompson, Attorney-in-Fact for Matthew Hawryluk
Issuer symbol
N/A
Transactions as of
31 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Apr 2022, 16:32:23 UTC
Previous filing
19 Nov 2021
Next filing
05 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GRTS Common Stock Award $0 +21,612 +68% $0.000000 53,351 31 Jan 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRTS Stock Option (Right to Buy) Award $0 +129,675 $0.000000 129,675 31 Jan 2022 Common Stock 129,675 $5.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") which vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 12,139 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 31,412 RSUs which vest over time measured from the grant date.
F3 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from January 31, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Executive Vice President and Chief Business Officer